IN BRIEF: Oxford BioDynamics director Diggle raises stake to 15%

Thu, 18th Nov 2021 16:20

Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Non-Executive Director Stephen Diggle buys 2.5 million shares via Vulpes Life Sciences Fund and Vulpes Testudo Fund at average 45.5 pence, worth GBP1.1 million, on Tuesday. Diggle now is interested in 14.7 million shares, a 14.7% stake.

Current stock price: 43.30p, up 0.7% on Thursday

Year-to-date change: down 48%

By Tom Waite; thomaslwaite@alliancenews.com

Related Shares

More News

21 May 2024 14:06

Oxford BioDynamics to provide tests to largest UK charitable hospital

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

3 Apr 2024 14:31

Oxford BioDynamics reaches "important milestone" with new laboratory

(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate sc...

14 Mar 2024 16:53

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...